2023
Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.
Naqvi S, He H, Siddiqi R, Khan N, Khakwani K, Ayaz A, Singh P, Ho T, Bryce A, McGregor B, Xu W, Bin Riaz I. Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis. Journal Of Clinical Oncology 2023, 41: 695-695. DOI: 10.1200/jco.2023.41.6_suppl.695.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMixed treatment comparisonGraphical user interfaceTreatment comparisonsRule-based algorithmSystematic reviewUser interfaceSignificant PFS benefitAdditional survival benefitFirst-line treatmentCertainty of evidenceEfficacious treatment optionRenal cell carcinomaBayesian networkSignificant differencesQuality of lifeAutomated fashionRisk of toxicityEvidence synthesis frameworkImmunotherapy combinationsMRCC patientsOS benefitPFS benefitSynthesis frameworkTreatment toxicity
2021
A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma
Riaz I, He H, Ryu A, Siddiqi R, Naqvi S, Yao Y, Husnain M, Narasimhulu D, Mathew J, Sipra Q, Vandvik P, Joseph R, Liu H, Wang Z, Herasevich V, Singh P, Hussain S, Ho T, Bryce A, Pagliaro L, Murad M, Costello B. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. European Urology 2021, 80: 712-723. PMID: 33824031, DOI: 10.1016/j.eururo.2021.03.016.Peer-Reviewed Original ResearchConceptsInteractive tableGraphical user interfaceUser interfaceUser-friendly formatAdvanced programmingDisplay resultsInteractive mannerInteractive reviewNetworkSearch strategyCurrent approachesSparse direct evidenceMetastatic renal cell carcinomaData extractionTableFirst-line treatmentProgrammingUntreated metastatic renal cell carcinomaFormatMultiple treatment optionsRenal cell carcinomaInherent biasesAdverse eventsComplete responseFramework